CinCor Pharma, Inc., (CINC) News

CinCor Pharma, Inc., (CINC): $35.00

0.08 (+0.23%)

POWR Rating

Component Grades













Add CINC to Watchlist
Sign Up

Industry: Biotech


of 402

in industry

Filter CINC News Items

CINC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest CINC News From Around the Web

Below are the latest news stories about CinCor Pharma Inc that investors may wish to consider to help them evaluate CINC as an investment opportunity.

Wall Street gyrations may thwart deal closings, IPO outlook

In terms of doing mergers and acquisitions and raising money through initial public offerings, 2021 was huge. But 2022 may be vastly different.

Yahoo | January 27, 2022

CinCor Pharma Appoints June Lee to Its Board of Directors

BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the appointment of the independent member June Lee, M.D. to the company’s Board of Directors. Dr. Lee brings decades of leadership experience in the biotechnology and pharmaceutical industry and has served in numerous executive and board roles. “We are very pleased to welcome June to the CinCor Board,” said James Healy, M.D., Ph.D., Chairman of CinCor’s Board of Directors. “As the Company’s clinical prog

Yahoo | January 13, 2022

10 Best Stocks to Buy on the Nasdaq Right Now

When you’re looking for stocks to buy there are so many things you can take into account, but starting with looking at the markets themselves is a good tactic. With such a blistering performance in the benchmark indices throughout most of the post-pandemic months, it may have been inevitable that a correction would occur. Just like the real world, investor sentiment features a gravitational pull: nothing can go up forever. Having said that, not all indices have suffered equally, presenting a con

Yahoo | January 13, 2022

CinCor Pharma's stock opens well above IPO price, then sells off sharply

CinCor Pharma Inc.'s stock shot out of the gate in morning trading Friday, but then pulled back sharply, to trade briefly below in negative territory. The Massachusetts-based biopharmaceutical company's stock's first trade was at $21.00 at 11:05 a.m. Eastern, or 31.3% above the $16 IPO price. The stock then rose to an intraday high of $22.67, before selling off to trade as low as $15.69, or 1.9% below its IPO price, before bouncing slightly to trade flat. At current prices, the company is valued

Yahoo | January 7, 2022

CinCor Pharma raised $194 million as upsized IPO prices in middle of expected range

CinCor Pharma Inc. is set to go public on the Nasdaq Friday, after the Massachusetts-based biopharmaceutical company's upsized initial public offering priced overnight at $16 a share, in the middle of the expected range of between $15 and $17 a share. The company raised $193.6 million as it sold 12.1 million shares in the IPO, up from previous expectations of an 11.0 million share offering. The IPO pricing values the company at about $566.7 million. Morgan Stanley, Jefferies and Evercore ISI are

Yahoo | January 7, 2022

CinCor Pharma Announces Pricing of Initial Public Offering

BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced the pricing of its initial public offering of 12,100,000 shares of common stock at a price to the public of $16.00 per share. The gross proceeds to CinCor from the offering, before deducting the underwriting discounts and com

Yahoo | January 7, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4887 seconds.